- Date2025-02-11
Publication of Review Result of the 1st Pharmaceutical Reimbursement Evaluation Committee of 2025
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu) releases the results of the deliberations of the 1st Pharmaceutical Reimbursement Evaluation Committee in 2025 as follows.
○ Result of the review of the adequacy of the healthcare benefit for the pharmaceutical applied for assessment
|
Product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Tevimbra inj. 100mg (Tislelizumab) |
BeiGen Korea |
Esophageal squamous cell carcinoma |
Reimbursement is adequate. |
|
Ofev Soft Cap. 100, 150mg(Nintedanib) |
Boehringer Ingelheim |
Idiopathic pulmonary fibrosis 2. Systemic sclerosis-associated interstitial lung disease 3. Progressive pulmonary fibrosis |
Reimbursement is adequate. Target: Systemic sclerosis-associated interstitial lung disease, |
|
Pemazyre Tab. 4,5,9,13.5mg (Pemigatinib) |
Handok |
FGFR2 fusion or rearrangement biliary tract cancer |
Reimbursement is adequate. |
○ Evaluation results of the expanded scope of use for risk-sharing agreement pharmaceutical
|
Product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Lorviqua Tab. 25,100mg (Lorlatinib) |
Pfizer |
Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer |
Reimbursement is adequate when accepted at or below assessed value. |
|
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The final evaluation results may be subject to change if there are changes in the detailed reimbursement scope and items of the drug, changes in the approval of the item applied for decision, or revocation (cancellation) of the approval. |
